Synapse

← Paul M. Ridker

Papers by Paul M. Ridker

Page 4 · newest first

  1. Adverse Effects of Low‐Dose Methotrexate in a Randomized Double‐Blind Placebo‐Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction TrialACR Open Rheumatology · 2020
  2. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular RiskJAMA · 2020
  3. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionAmerican Heart Journal · 2020
  4. Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS TrialCancer Research · 2020
  5. Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular DiseaseJACC CardioOncology · 2020
  6. Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical TrialJournal of the American Heart Association · 2020
  7. Effects of Interleukin-1β Inhibition on Incident Hip and Knee ReplacementAnnals of Internal Medicine · 2020
  8. Pulmonary Adverse Events in Patients Receiving Low‐Dose Methotrexate in the Randomized, Double‐Blind, Placebo‐Controlled Cardiovascular Inflammation Reduction TrialArthritis & Rheumatology · 2020
  9. Association of Migraine With Aura and Other Risk Factors With Incident Cardiovascular Disease in WomenJAMA · 2020
  10. Role of Rare and Low-Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid LevelsCirculation Genomic and Precision Medicine · 2020
  11. The relation between healthy lifestyle changes and decrease in systemic inflammation in patients with stable cardiovascular diseaseAtherosclerosis · 2020
  12. Effects of Interleukin-1β Inhibition on Incident AnemiaAnnals of Internal Medicine · 2020
  13. Cross-trait analyses with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headacheTyöväentutkimus Vuosikirja · 2020
  14. Adverse Effects of Low-Dose MethotrexateAnnals of Internal Medicine · 2020
  15. Targeting cardiovascular inflammation: next steps in clinical translationEuropean Heart Journal · 2020
  16. Hypothyroidism and Kidney Function: A Mendelian Randomization StudyThyroid · 2020
  17. Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk—A ReviewThrombosis and Haemostasis · 2019
  18. Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory RiskHypertension · 2019
  19. Catechol‐O‐Methyltransferase and Cardiovascular Disease: MESAJournal of the American Heart Association · 2019
  20. Prospective Evaluation of a Breast Cancer Risk Model Integrating Classical Risk Factors and Polygenic Risk in 15 Cohorts from Six Countries2019
  21. Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosisNature Communications · 2019
  22. Additive and Multiplicative Interactions Between Genetic Risk Score and Family History and Lifestyle in Relation to Risk of Type 2 DiabetesAmerican Journal of Epidemiology · 2019
  23. Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal AntibodiesBioDrugs · 2019
  24. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled TrialENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2019
  25. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolismBlood · 2019
  26. The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort studyEuropean Heart Journal · 2019
  27. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosisEuropean Heart Journal · 2019
  28. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potentialENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2019
  29. Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirinEuropean Heart Journal · 2019
  30. Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart diseasePLoS ONE · 2019
  31. Group IIA Secretory Phospholipase A ₂ , Vascular Inflammation, and Incident Cardiovascular DiseaseArteriosclerosis Thrombosis and Vascular Biology · 2019
  32. Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic DiseaseSHILAP Revista de lepidopterología · 2019
  33. Role of Rare and Low Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid Levels2019
  34. Anticytokine AgentsCirculation Research · 2019
  35. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trialsThe Lancet · 2019
  36. A large‐scale exome array analysis of venous thromboembolismGenetic Epidemiology · 2019
  37. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart FailureCirculation · 2019
  38. Genetics of fasting indices of glucose homeostasis using GWIS unravels tight relationships with inflammatory markers2018
  39. Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women’s Genome Health StudyArteriosclerosis Thrombosis and Vascular Biology · 2018
  40. Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean DietJAMA Network Open · 2018
  41. Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose MethotrexateArteriosclerosis Thrombosis and Vascular Biology · 2018
  42. Low-Dose Methotrexate for the Prevention of Atherosclerotic EventsNew England Journal of Medicine · 2018
  43. Psoriasis and AtherosclerosisCirculation Research · 2018
  44. Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?European Heart Journal · 2018
  45. COMT and Alpha-Tocopherol Effects in Cancer Prevention: Gene-Supplement Interactions in Two Randomized Clinical TrialsJNCI Journal of the National Cancer Institute · 2018
  46. Mendelian Randomization evaluation of causal effects of fibrinogen on incident coronary heart disease2018
  47. Should Aspirin Be Used for Primary Prevention in the Post-Statin Era?New England Journal of Medicine · 2018
  48. The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementationCurrent Opinion in Lipidology · 2018
  49. Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in WomenJournal of the American Heart Association · 2018
  50. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) studyAmerican Heart Journal · 2018